-
Mashup Score: 1
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC - 11 day(s) ago
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC - 13 day(s) ago
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC - 19 day(s) ago
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5FDA Grants Fast Track Designation to MVR-T3011 for Pretreated HNSCC - 2 month(s) ago
The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Setanaxib Plus Pembrolizumab Improves Survival in Recurrent/Metastatic HNSCC #hncsm #Oncology https://t.co/P4iZsUuhxA